Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
Sponsor: ViiV Healthcare
Summary
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
Official title: A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
564
Start Date
2026-06-29
Completion Date
2029-09-04
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
CAB ULA
CAB ULA will be administered.
RPV ULA
RPV ULA will be administered.
CAB LA
CAB LA will be administered.
RPV LA
RPV LA will be administered.